Diricore
Financiado
Exploiting vulnerabilities in protein synthesis for cancer diagnosis and therapy
Tumor growth requires continuous synthesis of proteins, nucleic acids and lipids that are important components of the cell. Demand for amino acids as the building blocks for protein synthesis in rapidly dividing tumor cells is oft...
Tumor growth requires continuous synthesis of proteins, nucleic acids and lipids that are important components of the cell. Demand for amino acids as the building blocks for protein synthesis in rapidly dividing tumor cells is often much higher than that of normal cells. Such increased demand can represent a vulnerability of the tumor. Importantly, this vulnerability is already being exploited for therapy in one instance: Addition of L-asparginase - an enzyme lowering the concentration of the amino acid asparagine in blood - to chemotherapy against acute lymphoblastic leukemia, resulted in a dramatic increase in cure from 5% to 95% of patients treated. Recent scientific publications highlight the fact that tumors are often metabolically rewired, and multiple examples of altered amino acid demand and/or turnover have been demonstrated in different cancer indications. Multiple drugs are under development that target amino acid availability, uptake or biosynthesis.
The challenge is to identify the potential sensitivity of individual tumors to such drugs.
Recently, we developed diricore, a procedure for determination of restrictions in the availability of particular amino acids for protein synthesis. To demonstrate the potential for diricore’s diagnosis capability in cancer, revealing proline limitations for protein synthesis in kidney cancer. We also used kidney cancer cell lines to verify sensitivity to proline deprivation, suggesting therapeutic possibilities.
We propose here to develop diricore towards a commercial diagnostic platform for determining limiting amino acid availability profiles in cancer patients. This information will guide physicians in taking dietary measures or prescribing drugs that inhibit amino acid uptake or biosynthesis.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2015-04-29
Fecha Fin: 2016-10-31
Fecha Fin: 2016-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2016-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2014:
ERC Proof of Concept Grant
Cerrada
hace 10 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
STICHTING HET NEDERLANDS KANKER INSTITUUTANTO...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
848.42K€ |
Participante